13F HOLDINGS REPORT
Sanofi
Quarter ended Q3 2025 · Filed November 4, 2025 · Accession 0001193125-25-263831
Total Value
$260.4M
Positions
9
Other Managers
0
Confidential Omitted
No
Holdings (9)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | MeiraGTx Holdings plc | MGTX | 12,197,737 | $100.4M | 38.56% |
| 2 | Novavax | NVAX | 6,880,481 | $59.7M | 22.91% |
| 3 | Inhibrx Biosciences, Inc. | INBX | 1,157,926 | $39.0M | 14.98% |
| 4 | AnaptysBio | ANABV | 821,917 | $25.2M | 9.67% |
| 5 | Immuneering Corp | IMRX | 2,708,559 | $19.0M | 7.28% |
| 6 | Omada Health Inc. | OMDA | 524,903 | $11.6M | 4.46% |
| 7 | LAVA Therapeutics N.V. | N51517105 | 1,919,455 | $3.0M | 1.15% |
| 8 | Eledon | ELDN | 814,980 | $2.1M | 0.81% |
| 9 | Q32 Bio Inc. | QTTB | 244,083 | $483,284 | 0.19% |